Bio-pharmaceuticals Industry in India (2018-2023)

Aarkstore Market Research Enterprise entitles the new approach into a Market Research Report “Bio-Pharmaceuticals Market In India

Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. The biotechnology industry comprises bio-pharmaceuticals, bio-agriculture, bio-informatics, bio-services, and bio-industry.

Bio-pharmaceuticals Industry in India (2018-2023)

Market insights:
The bio-pharmaceuticals market in India is expected to reach a value of INR 2,891.70 Bn in FY 2023, expanding at a compound annual growth rate (CAGR) of ~31.7% since FY 2018. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications. Currently, bio-pharmaceuticals is one of the fastest growing biotechnology segments in India. The significant bio-pharmaceutical clusters of India are located in Haridwar, Sikkim, Hyderabad, Vishakhapatnam, Chennai, Pondicherry, Mysore, Mumbai, Ahmedabad, and Delhi NCR.

Government initiatives and investments:
The major investors in the Indian bio-pharmaceutical market are AstraZeneca, Johnson & Johnson, GlaxoSmithKline (GSK), Nipro and Otsuka. In 2017, 46 mergers and acquisition (M&A) deals were signed in the Indian bio-pharmaceutical market, generating business worth INR 94.77 Bn. The Indian government has taken the initiative to set up an electronic platform for regulating online pharmacies. ‘Pharma Vision 2020’ has been unveiled so that India can emerge as a global leader in terms of end-to-end drug manufacturing.

Key growth drivers of the market:
India comprises of ~0.13 Mn highly skilled and experienced scientists who serve as a strong support system for the business process of the bio-pharmaceutical industry. With the help of the educational qualifications and skillset of these people, India is considered to be a significant center for bio-pharmaceutical research and development (R&D), especially for vaccine manufacturing.
The Government of India has approved an investment of INR 15,000 Mn under the Innovate in India (i3) program, for collaboration of industrial organizations and academic organizations over the next five years. This program is considered to act as a significant action of the Government in its way of boosting bio-pharmaceutical production in the country.

Key deterrents to the growth of the market:

It often takes a long time for the manufacturing companies to launch a new market-ready bio-pharmaceutical product in India due to the existence of numerous regulatory challenges in the process.
Also, the Indian bio-pharmaceutical industry lacks proper infrastructure regarding limited government-sponsored laboratory space, consumables, chemical components, and equipment, which acts as a significant hindrance to the growth of the market.

Companies covered:
Biocon Ltd.
Cadila Healthcare Ltd.
Dr. Reddy’s Laboratories Ltd.
Panacea Biotec Ltd.
Wockhardt Ltd.
GSK Pharmaceuticals Ltd.
Bharat Biotech International Ltd.
Bharat Serums and Vaccines Ltd.
Indian Immunologicals Ltd.
Serum Institute of India Pvt. Ltd.

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Our website:
Our blog:
Follow us on LinkedIn –




Aarkstore Enterprise provides businesses, start- ups, market research seekers and enthusiasts with all-inclusive yet exclusive market information encompassing a number of industry verticals. As a leading online market research reseller, Aarkstore acts as a platform for accessing statistics, forcasts, business insights, ideas, concepts and much more.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *